The multiple systemic artery to pulmonary artery fistulas resulting in severe irreversible pulmonary arterial hypertension in patient with previous history of pneumothorax
Systemic artery to pulmonary artery fistulas (SA-PAFs), are extremely rare in people without congenital heart disease. In this group of patients pulmonary arterial hypertension was reported in the single case. Then, we describe a case of multiple SA-PAFs, which were the cause of severe nonreversible arterial pulmonary hypertension in a patient who had a right-sided pneumothorax 35 years earlier.
52-year-old male Caucasian patient with echocardiographically confirmed pulmonary hypertension (PH) was admitted to cardiology department due to exertional dyspnea and signs of right ventricle failure. Routine screening for causes of secondary PH was negative. Right heart catheterization (RHC) confirmed a high degree arterial PH [mean pulmonary artery pressure (mPAP); 50,6 mmHg, pulmonary wedge pressure (PWP); 11,3 mmHg, pulmonary vascular resistance (PVR); 11,9 Wood’s units (WU)] irreversible in the test with inhaled nitric oxide. Oxygen saturation (SaO2) of blood samples obtained during the first RHC ranged from 69.3 to 73.2%. Idiopathic pulmonary arterial hypertension was diagnosed. Treatment with inhaled iloprost and sildenafil was initiated.
Control RHC, performed 5 months later showed values of mPAP (59,7 mmHg) and PVR (13,4 WU) higher in comparison to the initial measurement, SaO2 of blood obtained during RHC from upper lobe artery of the right lung was elevated and amounted 89.7%.
Then, pulmonary arteriography was performed. Lack of contrast in the right upper lobe artery with the evidence of retrograde blood flow visible as a negative contrast in the right pulmonary artery was found. Afterwards, right subclavian artery arteriography detected a huge vascular malformation communicating with right upper lobe artery. Following computed tomography angiogram (angio-CT) additionally revealed the enlargement of bronchial arteries originated fistulas to pulmonary artery of right upper lobe.
In spite of intensive pharmacological treatment, including the therapy of pulmonary hypertension and percutaneous embolisation of the fistulas, the patient’s condition continued to deteriorate further. He died three months after embolisation due to severe heart failure complicated by pneumonia.
Non-congenital SA-PAFs are extremely rare, however, they should be excluded in patients with pulmonary arterial hypertension and history of inflammatory or infectious disease of the lung and pleura, pneumothorax, cancer or Takayashu’s disease and after chest trauma.
KeywordsSystemic artery to pulmonary artery fistulas Pulmonary arterial hypertension Pneumothorax
Diastolic arterial blood pressure
Systolic arterial blood pressure
Computed tomography angiography
Human immunodeficiency virus
High-resolution computed tomography
International normalized ratio
Mean arterial blood pressure
Mean pulmonary artery pressure
N-terminal pro-brain natriuretic peptide
Diastolic pulmonary artery pressure
Systolic pulmonary artery pressure
Parts per million
Venous blood oxygen saturation
Pulmonary vascular resistance index
Pulmonary artery wedge pressure
Right atrium pressure
Right heart catheterization
Right ventricle systolic pressure
Systemic blood oxygenation
Systemic artery to pulmonary artery fistulas
Systemic vascular resistance index
Tricuspid annular plane systolic excursion
World health organization
Systemic artery to pulmonary artery fistulas (SA-PAFs) are known to develop in patients with congenital heart diseases, which are combined with right ventricular outflow or pulmonary artery obstruction and in many cases it may be the only blood supply to pulmonary circulation .
SA-PAFs are extremely rare in people with normal pulmonary circulation. They can be congenital and non-congenital. Non-congenital fistulas can develop in patients with inflammatory or infectious disease of the lung and pleura, cancer, Takayasu’s disease, or after trauma [2, 3, 4]. Congenital SA-PAFs can be detected in patients without any of the above-mentioned risk factors .
SA-PAF can be single or multiple and connect pulmonary vascular bed with left internal mammary artery, left subclavian artery, pericardiacophrenic branch of left inferior phrenic artery, left bronchial artery, gastric arteries or others [5, 6]. SA-PAFs are usually asymptomatic. Some patients complained about dyspnea, hemoptysis or symptoms of congestive heart failure [7, 8, 9, 10, 11]. The natural outcome of SA-PAFs is not well-known yet. SA-PAFs may be managed by embolisation, resection, or observation .
Only in two reported cases of congenital SA-PAFs mild elevated systolic pulmonary artery pressure (to 37 mmHg) was detected  and severe pulmonary arterial hypertension was reported in one case of congenital SA-PAFs .
We describe a case of non-congenital multiple SA-PAFs which were the cause of severe precapillary pulmonary hypertension in a patient who had right-sided pneumothorax thirty years earlier.
A 52-year-old male patient with initial diagnosis of pulmonary arterial was admitted to the Department of Cardiology for medical assessment and decision on further treatment. The patient had a history of right-sided spontaneous pneumothorax, treated with thoracentesis and vacuum drainage 35 years earlier. The patient felt increasing dyspnea on exertion. He also complained about signs of right ventricle failure and cyanosis. Four years earlier the patient was hospitalized three times for paroxysmal atrial fibrillation that was converted to sinus rhythm by electric cardioversion besides electrocardiographic examination was normal.
In the same year coronary angiography indicated normal coronary arteries. Echocardiography revealed mild pulmonary hypertension with calculated right ventricle systolic pressure of 36 mmHg without right ventricle dilation.
Timeline – history, course of the disease, diagnosis and treatment
Hospitalized three times for atrial fibrillation and heart failure echocardiography, cardioversion, coronarography were performed. Every time discharged from the departments with diagnosis: Atrial fibrillation, Heart failure, NYHA class II.
Increasing growing shortness of breath and symptoms of heart failure. Patient was hospitalized 3 times. Indirect features of pulmonary hypertension in echocardiography were detected. Three times chest-CT examination was performed; pulmonary embolism or chronic thromboembolic pulmonary arterial hypertension (2 x angio-CT) or pulmonary fibrosis (high resolution computer tomography) was excluded.
Diagnosis of pulmonary hypertension was established, WHO class III.
Admission to cardiology clinic – echocardiography (TTE, TEE), 6-min walking test, NT-proBNP, right heart catheterisation, pulmonary vasoreactivity test.
Diagnosis of irreversible arterial pulmonary hypertension was established.
Treatment with the illoprost and sildenafil has started
control visit – improvement in WHO class, decrease of NT-proBNP concentration and increase of 6-min test distance
Control RHC. SaO2 of blood samples obtained during RHC from upper lobe artery of the right lung amounted 87%.
Angiographic diagnostic of pulmonary arteries revealed PAH fistulas between subclavian and upper lobe of right lung arteries
angio-CT of systemic arteries revealed additional presence of bronchial artery fistulas to upper lobe of right lung arteries
Embolisation of fistulas
Death as a result of worsening of heart failure combined with pneumonia.
At admission to our clinic functional class of patient was assessed as WHO III, In physical examination the second heart sound (S2) was accentuated with widened split S2. Moreover, heart auscultation indicated holosystolic murmur of tricuspid regurgitation. The auscultation of the chest did not show a vascular murmur. Peripheral and central cyanosis was marked. Hepatomegaly, peripheral edema and varicose veins bilaterally were examined.
SaO2 obtained by pulse oximetry method was reduced to 88%. Electrocardiography revealed atrial fibrillation, right axis deviation and negative T wave in precordial leads v1-v3. Additional tests were as follows: NT-proBNP concentration – 3383 pg/ml, six-minute walking test distance - 373 m with 7/10 points in Borg dyspnea score.
SaO2 of blood obtained from radial artery was reduced to 87,8%. Right heart catheterization was performed. SaO2 of blood samples obtained during RHC from vena cava superior, vena cava inferior, right atrium, pulmonary trunk, middle lobe artery of the right lung and left pulmonary artery amounted respectively: 64,8%; 77,4%; 73,2%; 70,2%, 69,3%; 71,2% and did not indicate the presence of a left-to-right shunt.
Results of pulmonary arterial hypertension reversibility test
NO/O2 (80 ppm)
Sildenafil (50 mg)
NO/O2 (80 ppm)
Based on the whole clinical data and the results of RHC, a diagnosis of idiopathic irreversible pulmonary hypertension was established.
Treatment with inhaled iloprost (Ventavis) 6 × 5 μg and sildenafil (Revatio) orally 3 × 20 mg was initiated. Moreover, digoxin (0,1 mg daily), warfarin (INR range: 2–3), furosemide (40 mg orally daily) and spironolactone (100 mg daily) were administered.
Noninvasive follow up was performed one month later – the patient reported improved physical capacity, class II WHO, NT-proBNP concentration: 1014 pg/ml. Six-minute walking test distance - 471 m.
Invasive assessment was done five months later. RHC showed higher than in initial measurements values of PAP [75,4/51,8 (59,7) mm Hg] and PVR (13,4 WU) (Table 2 – control RHC).
Oxygen saturation of blood samples obtained during RHC from upper lobe artery of the right lung was elevated and amounted 89.7%.
Selective embolisation of fistulas was performed (50% mixture of Lipiodol and monomeric n-butyl-2-cyanoacrylate glue). Embolisation did not bring any clinical change in the patient’s condition.
Discussion and conclusions
A case of 52-year-old male patient with high-grade pulmonary arterial hypertension leading to severe right ventricle failure that was irreversible in vasoreactivity testing with inhaled nitric oxide and sildenafil was reported. Patient had a right-sided pneumothorax 35 years earlier.
Multiple artery-to-artery fistulas between systemic and pulmonary circulation, existing despite normal morphologic development of pulmonary circulation were the cause leading to severe pulmonary hypertension.
During the last four years of his life, the patient presenting with cyanosis and echocardiographic evidence of pulmonary hypertension and had normal spirometry results, HRCT and angio-CT of pulmonary arteries.
It may be possibly related to ventilation/perfusion mismatch , low diffusion capacity, low mixed venous PvO2 [16, 17], and sometimes existing right-to-left shunting, which is classically considered to arise from the reopening of patent foramen ovale [14, 18]. In this case normal chest radiographs, HRCT of the chest, and lack of pulmonary edema during vasodilatatory therapy excluded pulmonary veno-occlusive disease as the cause of hypoxemia .
We believe that in this case the probable cause of pulmonary hypertension are multiple systemic to pulmonary artery fistulas which initially cause left-to-right shunt, induce an increase in pulmonary vascular resistance which leads to an increase in pulmonary vascular resistance which eventually results in reversal of the direction of the shunt. It was responsible for the proper perfusion of the upper lobe of right lung during first two angio-CT.
In contrast, in the first RHC the ratio of mean pulmonary to systemic pressure was about 5/8, which clearly indicates the left-to-right direction of the shunt. This may be related to worsening function of right ventricle.
At the stage of the first RHC, we had no premises to extend the diagnosis towards systemic-pulmonary shunt. Moreover, unfortunately, the blood sample for the SaO2 was taken from the middle lobe artery of the right lung. After establishing the diagnosis of idiopathic pulmonary arterial hypertension, we included PAH treatment in accordance with the ESC standards. Control RHC has become a contribution to the diagnosis of multiple system-pulmonary fistulas. Only then did the patient inform us about a right-sided pneumothorax 35 years earlier.
The course of changes in pulmonary hemodynamics can be compared to changes in congenital heart defects leading to the development of the Eisenmenger syndrome but due to the observed clinical improvement, we did not decide to replace iloprost and sildenafil for the recommended endothelin-receptor antagonist . Furthermore, co-occurrence of idiopathic pulmonary arterial hypertension and systemic pulmonary fistulas can’t be clearly excluded.
Finally after many discussions within the heart team, selective embolisation of fistulas was performed. Unfortunately, despite effective embolization, changes in pulmonary circulation were so advanced that removal of the cause of pulmonary hypertension did not improve the patient’s condition. In addition, closure of the fistulas blocked the “potentially” beneficial effect of right ventricular decompression in the event of a re-growth of pulmonary artery pressure to super systemic values.
In spite of intensive pharmacological treatment, including the therapy of pulmonary hypertension the patient’s condition deteriorated further. He died three months later due to severe heart failure complicated by pneumonia.
Ji-Feng Li et al. described a similar case of multiple fistulas between systemic and pulmonary arteries of right lung, which were of congenital origin. They resulted in moderate pulmonary hypertension with mean PAP value = 37 mmHg. The right ventricle function was not seriously depressed; TAPSE = 18,5 mm. Embolisation of the largest fistula resulted in a gradual drop of mPAP in six-month follow-up despite the lack of PDE5-I, ARB or prostanoids in concomitant therapy .
Take home message
Non congenital SA-PAFs are extremely rare, but still the diagnosis should be considered when a shunt is suspected during the diagnostic work up of pulmonary arterial hypertension, especially in patients with risk factors.
The design of the case report, analysis, and interpretation of data and writing of the manuscript had no funding. If the case report is accepted for publication, the Medical University of Silesia will cover the related costs.
Availability of data and materials
All data presented come from the patient’s medical records and after their disclosure individual privacy of patient could be compromised.
All data generated or analyzed during this study are included in this published article.
“WJ” performed all right heart catheterizations, diagnosed fistulas between subclavian artery and pulmonary artery and analyzed and co-interpreted the patient data regarding pulmonary circulation, hypertension and pulmonary hypertension reversibility test results. In addition to diagnostics, he conducted pharmacological treatment of the patient and was a major contributor to the writing of the manuscript. “AT” participated in right heart catheterization and analyzed and co-interpreted the patient data regarding pulmonary circulation and hypertension. He was a contributor to the writing of the manuscript. “MK” analyzed and co-interpreted the patient data regarding pulmonary circulation and hypertension. He was a contributor to the writing of the manuscript. “RP” analyzed and co-interpreted the patient data regarding pulmonary circulation and he performed procedure of fistulas embolisation. He was a contributor to the writing of the manuscript. “JG”diagnosed additional fistulas between aorta and pulmonary artery, analyzed and co-interpreted the patient data regarding pulmonary circulation. He was a contributor to the writing of the manuscript. “ATor” analyzed and co-interpreted the patient data regarding pulmonary circulation and hypertension. “ENK” analyzed and co-interpreted the patient data regarding pulmonary hypertension. “CW” participated in right heart catheterizations, she co-diagnosed fistulas between subclavian artery and pulmonary artery and analyzed and co-interpreted the patient data regarding pulmonary hypertension and pulmonary hypertension reversibility test results. She performed echocardiography examinations. In addition to diagnostics, she conducted pharmacological treatment of the patient and was a contributor to the writing of the manuscript. All authors read and approved the final manuscript.”
“WJ” – cardiologist, pulmonary hypertension specialist, deputy head of the 2nd Department of Cardiology and head of cardiac cath-lab of the 2nd Department of Cardiology of School of Medicine with Dentistry Division in Zabrze, Medical University of Silesia, 10 Ci-Sklodowska str., 41–808 Zabrze, Poland.
“AT” – cardiologist, pulmonary hypertension specialist, deputy head of cardiac cath-lab of the 2nd Department of Cardiology of School of Medicine with Dentistry Division in Zabrze, Medical University of Silesia, 10 Ci-Sklodowska str., 41–808 Zabrze, Poland.
“MK” – cardiologist, pulmonary circulation and hypertension specialist, deputy head of the Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Centre of Postgraduate Medical Education, European Health Centre Otwock, 14/18 Borowa str, 05–400 Otwock, Poland. Polish Society of Cardiology expert.
“RP” – interventional radiologist, head of Department of Interventional Radiology, Department of Radiography Medical, University of Lublin, Staszica 11 str., 20–081, 20–954 Lublin, Poland.
“JG” – radiologist, lecturer of Department of Radiology and Nuclear Medicine, School of Medicine with Dentistry Division in Zabrze, Medical University of Silesia, 13–15 3-go Maja str., 41–800 Zabrze, Poland.
“ATor” – cardiologist, pulmonary circulation and hypertension specialist, head of the Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Centre of Postgraduate Medical Education, European Health Centre Otwock, 14/18 Borowa str, 05–400 Otwock, Poland. European Society of Cardiology expert.
“ENK” – cardiologist, head of the 2nd Department of Cardiology of School of Medicine with Dentistry Division in Zabrze, Medical University of Silesia, 10 Ci-Sklodowska str., 41–808 Zabrze, Poland.
“CW” – cardiologist, pulmonary hypertension specialist, head of echocardiography laboratory of the 2nd Department of Cardiology of School of Medicine with Dentistry Division in Zabrze, Medical University of Silesia, 10 Ci-Sklodowska str., 41–808 Zabrze, Poland.
Ethics approval and consent to participate
Presented case report was reviewed by the Bioethics Committee of the Medical University of Silesia, reference number; KNW/0022/KB/7/8.
Consent for publication
Manuscript does not contain any individual person’s data in any form. During life, the patient gave consent for a case report publication. Because the patient died, written consent for the use of medical records was obtained from the wife of the patient.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 9.Gallet B, Bayet G, Saudemont JP, et al. Fistule syste’mopulmonaire acquise apre` s pleurectomie responsable d’un souffle thoracique continu. Cardiol Angeiol. 1988;37:305–8.Google Scholar
- 13.Jan Wodniecki, Wojciech Jacheć, Lech Poloński, Andrzej R. Tomasik, Celina Wojciechowska, Ala Foremny. Sildenafil obniża ciśnienie i opory płucne oraz zwiększa wrażliwość tętnic płucnych na tlenek azotu w pierwotnym nadciśnieniu płucnym. Przegląd Lekarski 2005 T.62 nr 2 s. 135–138.Google Scholar
- 20.Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery J-L, Barbera JA, Beghetti M, Corris P, Gaine S, Simon Gibbs J, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Rubin APL, Zellweger M, Simonneau G. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by: International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493–537.CrossRefGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.